MCL1 and acute myeloid leukemia: Besides, the ability of XL102 to modulate MCL1 levels in primary AML blasts, Venetoclax resistant cells, and xenograft models and observed synergistic anti-leukemic activities of combined XL102 and Venetoclax treatment may have therapeutic benefits in a genetically heterogeneous disease like AML.